Based on the presence of this novel FGFR2–CLIP1 fusion in his cancer, at the beginning of October, the patient enrolled in a Phase I/II clinical trial (NCT02393248) evaluating the safety and tolerability of an oral pan-FGFR inhibitor, INCB054828. The gene discussed is FGFR2; the disease is cancer.